Optimizing Gastroenterology InterQual Workflows with Klivira Automation

Navigating **gastroenterology InterQual** criteria is critical for securing approvals for high-cost biologics, advanced imaging, and complex procedures. Klivira's platform automates the intricate process of aligning clinical documentation with evidence-based medical necessity requirements.

Revenue cycle directors and prior authorization coordinators in gastroenterology face significant administrative burdens due to the volume and complexity of PA requirements. InterQual criteria, widely adopted by payers, introduce an additional layer of evidence-based review for medical necessity. Effectively managing these criteria is paramount to minimizing denials and ensuring timely patient access to essential GI treatments and diagnostics.

The Role of InterQual Criteria in Gastroenterology Prior Authorization

InterQual, a product of Change Healthcare (now Optum), provides evidence-based clinical criteria for medical necessity and level-of-care decisions. In gastroenterology, these medical necessity criteria are applied to a wide range of services, including high-cost specialty drugs, advanced diagnostic imaging, and complex endoscopic procedures. Understanding and proactively addressing InterQual requirements is fundamental for GI practices to secure timely prior authorizations and avoid costly denials.

Key Gastroenterology Services Requiring InterQual Review

IBD biologics (e.g., Humira, Stelara, Skyrizi, Entyrio) and specialty IBD drugs.
Advanced imaging such as MRCP, MR enterography, and CT enterography.
Endoscopic procedures with specific PA requirements, including capsule endoscopy (CPT 91110), ERCP, and EUS.
Hepatitis C direct-acting antivirals (e.g., Epclusa, Mavyret).
Bariatric surgery (gastric bypass, sleeve gastrectomy) in relevant practices.
Specialty drugs for functional GI disorders like IBS-D (e.g., Viberzi) and chronic constipation (e.g., Motegrity, Linzess, Trulance).

Aligning GI Clinical Documentation with InterQual Standards

InterQual criteria are rooted in clinical evidence and often align with guidelines from bodies like ACG, AGA, and AASLD. For GI prior authorizations, this translates into specific documentation requirements. For IBD biologics, payers frequently require confirmation of diagnosis, disease severity scores (e.g., Mayo score for UC, CDAI or Harvey-Bradshaw for Crohn's), prior conventional therapy trials, and pre-initiation screenings for TB and hepatitis. Similarly, advanced imaging and specialty functional GI drugs demand clear clinical questions, prior workup details, and adherence to diagnosis criteria (e.g., Rome criteria for IBS).

Common InterQual-Related Denial Drivers in Gastroenterology

Failure to meet step therapy requirements for IBD biologics (e.g., conventional therapy trial, biosimilar first).
Inadequate documentation of disease severity (e.g., missing Mayo score or CDAI).
Gaps in pre-biologic screening documentation for TB or hepatitis.
Insufficient prior workup or inappropriate-use criteria for advanced imaging (e.g., capsule endoscopy).
Misclassification of treatment-naive vs. treatment-experienced status for Hep C DAAs or IBD biologics.
Documentation not supporting diagnosis criteria (e.g., Rome criteria for IBS).

Klivira's Solution for Gastroenterology InterQual Automation

Klivira's platform is engineered to address the specific challenges of **gastroenterology InterQual** workflows. By integrating directly with EMRs, Klivira automates the extraction of necessary clinical data, such as disease severity scores, medication history, and diagnostic results. This ensures that submitted documentation precisely aligns with InterQual's evidence-based medical necessity criteria, significantly reducing the administrative burden and improving approval rates.

Enhancing Efficiency and Patient Access in GI

Beyond simply submitting data, Klivira’s solution incorporates ACG/AGA-guideline-aware step therapy logic for IBD biologic sequencing and automates treatment-status classification from EMR medication history. For Hep C DAAs, it streamlines workflows for genotype, fibrosis stage, and drug-interaction documentation. The platform also manages periodic re-authorization for chronic IBD treatments and intelligently routes medical-vs-pharmacy benefit claims, ensuring comprehensive coverage for complex GI cases.

Frequently asked questions

How does Klivira handle ongoing re-authorizations for chronic GI conditions like IBD?

Klivira's platform includes a dedicated workflow for periodic re-authorization of chronic treatments, such as IBD biologics. It tracks re-authorization cycles, prompts for updated clinical documentation of disease response, and automates the submission process to ensure continuous coverage, aligning with payer and InterQual requirements.

Can Klivira help with step therapy requirements for IBD biologics often enforced by InterQual?

Yes, Klivira's system incorporates ACG/AGA-guideline-aware step therapy logic specifically for IBD biologic sequencing. It helps ensure that the correct conventional therapy trials or biosimilar preferences are documented and followed, aligning with payer policies and InterQual criteria to prevent denials.

How does Klivira manage the medical vs. pharmacy benefit split for GI biologics?

Klivira's platform intelligently routes prior authorization requests based on the administration mode of biologic agents, distinguishing between provider-administered infusions (medical benefit) and self-administered injections (pharmacy benefit). This ensures the correct PA pathway is followed, even when a patient's treatment regimen changes benefit sides, minimizing delays.

What specific GI documentation does Klivira extract from the EMR for InterQual reviews?

Klivira extracts critical clinical data from the EMR, including diagnosis confirmations, disease severity assessments (e.g., Mayo score for UC, CDAI for Crohn's), prior conventional therapy trials, TB and hepatitis screening results, genotype and fibrosis stage for Hep C, and prior imaging history. This data is leveraged to meet InterQual's evidence requirements effectively.

Does Klivira support specific guidelines like ACG or AGA for GI prior authorizations?

Yes, Klivira's platform is designed with ACG and AGA guidelines in mind, particularly for IBD biologic sequencing and documentation requirements. This ensures that the automated workflows and data extraction align with established clinical best practices and payer expectations, strengthening medical necessity arguments for InterQual reviews.